Excitement for our future
        
        Excitement for our future | 
      
        | https://doi.org/10.18632/oncotarget.28116John L. Marshall | 
      
                  | 2307-2307 | 
    
    
    
      
                
                                
                                
                      
            
                    Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data
        
        Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data | 
      
        | https://doi.org/10.18632/oncotarget.28114Timothy Craig Allen,
                        Yan Xiao,
                        Baiyu Yang,
                        Denise Croix,
                        Anup Abraham,
                        Stella Redpath,
                        Julia Engstrom-Melynk,
                        Roma Shah,
                        Jaya Madala,
                         and Eric H. Bernicker | 
      
                  | 2308-2315 | 
    
    
    
      
                
                                
                                
                      
            
                    Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)
        
        Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC) | 
      
        | https://doi.org/10.18632/oncotarget.27995Yihe Yan,
                        Leting Zheng,
                        Qiang Du,
                         and David A. Geller | 
      
                  | 2316-2317 | 
    
    
    
      
                
                                
                                
                      
            
                    Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
        
        Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer | 
      
        | https://doi.org/10.18632/oncotarget.27998Anne E. O’Shea,
                        Guy T. Clifton,
                         and George E. Peoples | 
      
                  | 2318-2319 | 
    
    
    
      
                
                                
                                
                      
            
                    Correction: P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis
        
        Correction: P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis | 
      
        | https://doi.org/10.18632/oncotarget.27449Jun Zhang,
                        Ke Ma,
                        Tingting Qi,
                        Xiaoning Wei,
                        Qing Zhang,
                        Guanwu Li,
                         and Jen-Fu Chiu | 
      
                  | 2320-2320 | 
    
    
    
      
                
                                
                                
                      
            
                    Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
        
        Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel | 
      
        | https://doi.org/10.18632/oncotarget.27474Manabu Seino,
                        Tsuyoshi Ohta,
                        Akiko Sugiyama,
                        Hirotsugu Sakaki,
                        Takeshi Sudo,
                        Seiji Tsutsumi,
                        Shogo Shigeta,
                        Hideki Tokunaga,
                        Masafumi Toyoshima,
                        Nobuo Yaegashi,
                         and Satoru Nagase | 
      
                  | 2321-2322 |